• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sales of Stem Cell Products Expected to Surpass $35 Million in 2007, Leading Medical Industry Analyst Says

Posted on: Monday, 8 January 2007, 09:01 CST

PHILADELPHIA, Jan. 8 /PRNewswire/ -- Sales of stem cell products in the United States reached $16.4 million last year and are expected to surpass $35 million in 2007, according to Robin R. Young, a medical industry analyst who has been named one of The Wall Street Journal's "Best on the Street" and among the top-10 analysts in the United States by Institutional Investor.

The products, derived from allogenic or autologous stem/progenitor cells, are used primarily by orthopedic surgeons to stimulate bone growth in cases involving spinal repair (fusion and nucleus repair), fresh fractures and non-union fractures. More than 200 companies are preparing products for commercialization, including several stem cell therapies expected to enter the market in the coming 24-36 months for use in joint and cartilage repair cases.

"Strong sales in the orthopedics market resulted in higher-than-projected numbers in 2006," Young said. "Furthermore, initial patient outcomes were very promising. This has led to surgeon demand for stem cell products rising at an accelerating rate and pushing projections above our original forecast for 2007."

At the 2nd Annual Stem Cell Summit, which is set for Feb. 12 and 13 in San Diego, Young will kick off the largest gathering of stem cell company executives, scientists, investors and physicians with the presentation of a 10-year forecast for the use of stem/progenitor cells in cardiology, orthopedics, oncology, urology and other markets. The forecast will consist of stem cell product shipment, average selling price and revenue projections.

"Stem cell products represent a disruptive technology that is entering its third year of use in the operating room," added Young. "While orthopedics is the hotbed of stem cell product use today in the United States, many companies are progressing rapidly with their development of products to treat cardiac, oncologic, urologic and other indications. Furthermore, these companies are advancing the technology to include products derived from human embryonic stem cells."

The 2nd Annual Stem Cell Summit is a two-day conference that will bring together more than 35 companies as well as physicians and investors who will speak and present on the latest developments in embryonic and adult stem cells. In addition, the conference will host the first live stem cell surgery in which attendees can ask questions in real-time as surgeons use a stem cell product in the operating room.

Robin R. Young CFA has more than 23 years of experience as a medical industry analyst. He is the president and founder of Robin Young Consulting Group and RRY Publications, which publishes industry newsletters and produces the Stem Cell Summit. Earlier in his career, Young was instrumental in forming and managing HealthpointCapital's research and private equity practice. In addition, he was a Managing Director for Stephens Inc., Piper Jaffray & Co. and John G. Kinnard & Co.

For more information about the U.S. market forecast for stem cell products, contact Young via e-mail at robin@ryortho.com or call 877-817-6450. For more information about the 2nd Annual Stem Cell Summit, visit http://www.stemcellsummit.com/.

RRY Publications

CONTACT: Wendy Lau, +1-212-845-4272, wendy.lau1@eurorscg.com, or TimTilson, +1-858-646-3059, timothy.tilson@eurorscg.com, both of Noonan Russo,for RRY Publications

Source: PRNewswire

More News in this Category